PD-1 Blockade Enhances Therapeutic Effects of Anti-CEA ¹⁷⁷Lu-DOTA-M5A in Colorectal Cancer CEA-Transgenic Mice

Abstract

Tumor-targeted radioimmunotherapy (RIT) has the dual capability of delivering ionizing radiation to cancer cells while modulating the tumor microenvironment (TME) to enhance immune responses. These immune-stimulatory properties suggest that RIT could synergize with PD-1 blockade. However, the precise immune mechanisms underlying this potential synergy remain unclear. Here we show that ¹⁷⁷Lu-DOTA-M5A, the radiolabeled antibody against carcinoembryonic antigen (CEA), induces tumor regression and alters the TME when combined with PD-1 blockade in a colorectal cancer (CRC) model. Using in vitro uptake assays and in vivo studies in CEA-transgenic mice, we found that low-dose ¹⁷⁷Lu-DOTA-M5A (2.5 MBq) combined with anti-PD-1 achieved complete tumor control, with −6% growth rate, in contrast to limited efficacy from either monotherapy. This combination extended survival by more than 300% compared to controls, with no median survival reached. Remarkably, this effect was equivalent to that of high-dose monotherapy (5 MBq), indicating a potent synergistic interaction. Immune profiling revealed that RIT altered lymphocyte infiltration, while the combination therapy shifted tumor-associated macrophages toward a pro-inflammatory phenotype. These immune-modulating effects occurred without inducing myelotoxicity. Our findings suggest that PD-1 blockade potentiates the therapeutic efficacy of ¹⁷⁷Lu-DOTA-M5A, supporting its development as a safe and effective combination strategy for CRC therapy.

Keywords

¹⁷⁷Lu-DOTA-M5A / carcinoembryonic antigen / combination therapy / PD-1 blockade / radioimmunotherapy

References

[1] M. J. Duffy, “Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?,” Clinical Chemistry 47, no. 4 (April 2001): 624–630.

[2] K. Björkman, S. Jalkanen, M. Salmi, et al., “A Prognostic Model for Colorectal Cancer Based on CEA and a 48-Multiplex Serum Biomarker Panel,” Scientific Reports 11, no. 1 (February 2021): 4287.

[3] S. Hammarström, “The Carcinoembryonic Antigen (CEA) Family: Structures, Suggested Functions and Expression in Normal and Malignant Tissues,” Seminars in Cancer Biology 9, no. 2 (April 1999): 67–81.

[4] C. Ordoñez, R. A. Screaton, C. Ilantzis, and C. P. Stanners, “Human Carcinoembryonic Antigen Functions as a General Inhibitor of Anoikis1,” Cancer Research 60, no. 13 (July 2000): 3419–3424.

[5] C. H. F. Chan, P. Camacho-Leal, and C. P. Stanners, “Colorectal Hyperplasia and Dysplasia Due to Human Carcinoembryonic Antigen (CEA) Family Member Expression in Transgenic Mice,” PLoS One [Internet] 2, no. 12 (December 2007): e1353, https://doi.org/10.1371/journal.pone.0001353.

[6] R. Schoffelen, G. W. T. A. van der, G. Franssen, et al., “Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colonic Tumors in Mice,” Journal of Nuclear Medicine 51, no. 11 (November 2010): 1780–1787.

[7] D. Akhavan, P. Yazaki, D. Yamauchi, et al., “Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients With Advanced Carcinoembryonic Antigen Producing Malignancies,” Cancer Biotherapy and Radiopharmaceuticals 35, no. 1 (January 2020): 10–15.

[8] M. Kujawski, M. Sherman, S. Hui, et al., “Potent Immunomodulatory Effects of an anti-CEA-IL-2 Immunocytokine on Tumor Therapy and Effects of Stereotactic Radiation,” Oncoimmunology 9, no. 1 (January 2020): 1724052.

[9] B. Cahan, L. Leong, L. Wagman, et al., “Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma,” Cancer Biotherapy and Radiopharmaceuticals 32, no. 7 (September 2017): 258–265.

[10] J. Y. C. Wong, D. Z. Chu, L. E. Williams, et al., “A Phase I Trial of 90Y-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients With Metastatic CEA-Producing Malignancies,” Cancer Biotherapy and Radiopharmaceuticals 21, no. 2 (April 2006): 88–100.

[11] S. E. Cha, M. Kujawski, P. J. Yazaki, C. Brown, and J. E. Shively, “Tumor Regression and Immunity in Combination Therapy With Anti-CEA Chimeric Antigen Receptor T Cells and Anti-CEA-IL2 Immunocytokine,” Oncoimmunology 10, no. 1 (January 2021): 1899469.

[12] J. H. Lee and S. W. Lee, “The Roles of Carcinoembryonic Antigen in Liver Metastasis and Therapeutic Approaches,” Gastroenterology Research and Practice 2017 (May 2017): e7521987.

[13] F. Buchegger, J. P. Mach, A. Pèlegrin, et al., “Radiolabeled Chimeric Anti-CEA Monoclonal Antibody Compared With the Original Mouse Monoclonal Antibody for Surgically Treated Colorectal Carcinoma,” Journal of Nuclear Medicine 36, no. 3 (March 1995): 420–429.

[14] J. Y. Wong, G. E. Thomas, D. Yamauchi, et al., “Clinical Evaluation of Indium-111-Labeled Chimeric Anti-CEA Monoclonal Antibody,” Journal of Nuclear Medicine 38, no. 12 (December 1997): 1951–1959.

[15] J. Y. C. Wong, S. Shibata, L. E. Williams, et al., “A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy With 5-Fluorouracil in Patients With Metastatic Colorectal Cancer,” Clinical Cancer Research 9, no. 16 (December 2003): 5842–5852.

[16] T. Mohajershojai, D. Spangler, S. Chopra, F. Y. Frejd, P. J. Yazaki, and M. Nestor, “Enhanced Therapeutic Effects of 177Lu-DOTA-M5A in Combination With Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts,” Cancers 15, no. 17 (January 2023): 4239.

[17] T. Mohajershojai, P. Jha, A. Boström, F. Y. Frejd, P. J. Yazaki, and M. Nestor, “In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer,” Frontiers in Oncology [Internet] 12 (2022): 849338, https://doi.org/10.3389/fonc.2022.849338.

[18] J. Y. Wong, L. E. Williams, D. M. Yamauchi, et al., “Initial Experience Evaluating 90yttrium-Radiolabeled Anti-Carcinoembryonic Antigen Chimeric T84.66 in a Phase I Radioimmunotherapy Trial,” Cancer Research 55, no. 23 Suppl (December 1995): 5929s–5934ss.

[19] S. Jin, Z. Shang, W. Wang, et al., “Immune Co-Inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study,” Journal of Immunotherapy 46, no. 4 (May 2023): 154–159.

[20] D. Bernard, J. D. Hansen, L. Du Pasquier, M. P. Lefranc, A. Benmansour, and P. Boudinot, “Costimulatory Receptors in Jawed Vertebrates: Conserved CD28, Odd CTLA4 and Multiple BTLAs,” Developmental & Comparative Immunology 31, no. 3 (January 2007): 255–271.

[21] A. Ribas and J. D. Wolchok, “Cancer Immunotherapy Using Checkpoint Blockade,” Science 359, no. 6382 (March 2018): 1350–1355.

[22] K. Lumniczky, S. M. Candéias, U. S. Gaipl, and B. Frey, “Editorial: Radiation and the Immune System: Current Knowledge and Future Perspectives,” Frontiers in Immunology 8 (January 2018): 1933.

[23] M. Zhu, M. Yang, J. Zhang, et al., “Immunogenic Cell Death Induction by Ionizing Radiation,” Frontiers in Immunology [Internet] 12 (2021): 705361, https://doi.org/10.3389/fimmu.2021.705361.

[24] E. B. Golden and L. Apetoh, “Radiotherapy and Immunogenic Cell Death,” Seminars in Radiation Oncology 25, no. 1 (January 2015): 11–17.

[25] M. Rückert, L. Deloch, R. Fietkau, B. Frey, M. Hecht, and U. S. Gaipl, “Immune Modulatory Effects of Radiotherapy as Basis for Well-Reasoned Radioimmunotherapies,” Strahlentherapie und Onkologie 194, no. 6 (June 2018): 509–519.

[26] D. B. Johnson, C. A. Nebhan, J. J. Moslehi, and J. M. Balko, “Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity,” Nature Reviews Clinical Oncology 19, no. 4 (April 2022): 254–267.

[27] D. T. Le, J. N. Uram, H. Wang, et al., “PD-1 Blockade in Tumors With Mismatch-Repair Deficiency,” New England Journal of Medicine 372, no. 26 (June 2015): 2509–2520.

[28] A. Ribas, “Adaptive Immune Resistance: How Cancer Protects From Immune Attack,” Cancer Discovery 5, no. 9 (September 2015): 915–919.

[29] P. F. Robbins, J. A. Kantor, M. Salgaller, P. H. Hand, P. D. Fernsten, and J. Schlom, “Transduction and Expression of the Human Carcinoembryonic Antigen Gene in a Murine Colon Carcinoma Cell Line,” Cancer Research 51, no. 14 (July 1991): 3657–3662.

[30] C. O. Sahlmann, K. Homayounfar, M. Niessner, et al., “Repeated Adjuvant Anti-CEA Radioimmunotherapy After Resection of Colorectal Liver Metastases: Safety, Feasibility, and Long-Term Efficacy Results of a Prospective Phase 2 Study,” Cancer 123, no. 4 (February 2017): 638–649.

[31] J. Y. C. Wong, D. M. Yamauchi, V. Adhikarla, et al., “First-In-Human Pilot PET Immunoimaging Study of 64Cu-Anti-Carcinoembryonic Antigen Monoclonal Antibody (hT84.66-M5A) in Patients With Carcinoembryonic Antigen-Producing Cancers,” Cancer Biotherapy and Radiopharmaceuticals [Internet] 38, no. 1 (September 2022): 0028, https://doi.org/10.1089/cbr.2022.0028.

[32] J. Y. C. null Wong, D. Z. Chu, D. M. Yamauchi, et al., “A Phase I Radioimmunotherapy Trial Evaluating 90yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients With Metastatic CEA-Producing Malignancies,” Clinical Cancer Research 6, no. 10 (October 2000): 3855–3863.

[33] City of Hope Medical Center, “A Phase I Study of Actinium-225 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced or Metastatic Cancers,” [Internet]. clinicaltrials.gov; February 2023, Report No.: NCT05204147, https://clinicaltrials.gov/study/NCT05204147.

[34] B. Lin, H. Du, J. Fan, et al., “Radioimmunotherapy Combined With Low-Intensity Ultrasound and Microbubbles: A Potential Novel Strategy for Treatment of Solid Tumors,” Frontiers in Oncology 11 (2021): 750741, https://doi.org/10.3389/fonc.2021.750741.

[35] M. Jain, G. Venkatraman, and S. K. Batra, “Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation,” Clinical Cancer Research 13, no. 5 (March 2007): 1374–1382.

[36] C. Liu, M. Yang, D. Zhang, M. Chen, and D. Zhu, “Clinical Cancer Immunotherapy: Current Progress and Prospects,” Frontiers in Immunology [Internet] 13 (2022): 961805, https://doi.org/10.3389/fimmu.2022.961805.

[37] S. C. Kleinendorst, E. Oosterwijk, J. Molkenboer-Kuenen, et al., “Towards Effective CAIX-Targeted Radionuclide and Checkpoint Inhibition Combination Therapy for Advanced Clear Cell Renal Cell Carcinoma [Internet],” Theranostics 14, no. 9 (2024): 3693–3707, https://doi.org/10.7150/thno.96944.

[38] “Acute Side Effects of Radiation Therapy” [Internet], accessed April 13, 2024, https://doi.org/10.1007/978-3-319-55950-6.

[39] D. Ersahin, I. Doddamane, and D. Cheng, “Targeted Radionuclide Therapy,” Cancers 3, no. 4 (October 2011): 3838–3855.

[40] J. B. Gorin, J. Ménager, S. Gouard, et al., “Antitumor Immunity Induced After α Irradiation,” Neoplasia 16, no. 4 (April 2014): 319–328.

[41] W. Zhong, J. S. Myers, F. Wang, et al., “Comparison of the Molecular and Cellular Phenotypes of Common Mouse Syngeneic Models With Human Tumors,” BMC Genomics 21, no. 1 (January 2020): 2.

[42] H. Chen, L. Zhao, K. Fu, et al., “Integrin Α_vβ₃-Targeted Radionuclide Therapy Combined With Immune Checkpoint Blockade Immunotherapy Synergistically Enhances Anti-Tumor Efficacy,” Theranostics 9, no. 25 (October 2019): 7948–7960.

[43] C. de Aguiar Ferreira, P. Heidari, B. Ataeinia, et al., “Immune Checkpoint Inhibitor-Mediated Cancer Theranostics With Radiolabeled Anti-Granzyme B Peptide,” Pharmaceutics 14, no. 7 (July 2022): 1460.

[44] Q. Shang, X. Yu, Q. Sun, H. Li, C. Sun, and L. Liu, “Polysaccharides Regulate Th1/Th2 Balance: A New Strategy for Tumor Immunotherapy,” Biomedicine & Pharmacotherapy 170 (2024): 115976.

[45] F. Klug, H. Prakash, P. E. Huber, et al., “Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS⁺/M1 Phenotype That Orchestrates Effective T Cell Immunotherapy,” Cancer Cell 24, no. 5 (2013 Nov 11): 589–602.

[46] P. J. Yazaki, M. A. Sherman, J. E. Shively, et al., “Humanization of the anti-CEA T84.66 Antibody Based on Crystal Structure Data,” Protein Engineering, Design and Selection 17, no. 5 (May 2004): 481–489.

[47] S. Bondza, E. Foy, J. Brooks, et al., “Real-Time Characterization of Antibody Binding to Receptors on Living Immune Cells,” Frontiers in Immunology 8 (2017): 455.

[48] J. Friedrich, C. Seidel, R. Ebner, and L. A. Kunz-Schughart, “Spheroid-Based Drug Screen: Considerations and Practical Approach,” Nature Protocols 4, no. 3 (March 2009): 309–324.

[49] P. Clarke, J. Mann, J. F. Simpson, K. Rickard-Dickson, and F. J. Primus, “Mice Transgenic for Human Carcinoembryonic Antigen as a Model for Immunotherapy,” Cancer Research 58, no. 7 (April 1998): 1469–1477.

[50] L. Modugno and S. Giannerini, “The Wild Bootstrap for Multilevel Models,” Communications in Statistics—Theory and Methods 44, no. 22 (November 2015): 4812–4825.

[51] A. Loy, S. Steele, and J. Korobova, “lmeresampler: Bootstrap Methods for Nested Linear Mixed-Effects Models” [Internet], 2022, https://CRAN.R-project.org/package=lmeresampler.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).